Bărboi Oana-Bogdana, Ciortescu Irina, Chirilă Ioan, Anton Carmen, Drug Vasile
Department of Gastroenterology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Institute of Gastroenterology and Hepatology, 'Saint Spiridon' Hospital, 700111 Iasi, Romania.
Exp Ther Med. 2020 Dec;20(6):185. doi: 10.3892/etm.2020.9315. Epub 2020 Oct 13.
At present, irritable bowel syndrome (IBS) is a common medical problem all over the world that implies considerable social burden and high costs. Considering the different pathophysiological pathways, unitary management for IBS is not possible. Of the therapeutic approaches that have been proposed so far, only a few have been demonstrated to have beneficial effects in IBS patients. The implication of gut microbiota in IBS is obvious, similarly to the therapeutic effect of pro-/prebiotics, which is reflected by the latest publications. The intake of inulin seems to regulate the bowel peristalsis and colonic transit, the consistency and frequency of the stools, as it changes the composition of gut microbiota. The beneficial effect of inulin in patients with IBS-constipation form (IBS-C) is obvious, but still, more randomized controlled clinical trials involving large samples of patients are needed in order to provide more evidence.
目前，肠易激综合征（IBS）是全球常见的医学问题，意味着巨大的社会负担和高昂的成本。考虑到不同的病理生理途径，对IBS进行统一管理是不可能的。在迄今为止提出的治疗方法中，只有少数已被证明对IBS患者有有益效果。肠道微生物群在IBS中的作用是显而易见的，益生元/益生菌的治疗效果也是如此，这在最新的出版物中有所体现。摄入菊粉似乎可以调节肠道蠕动和结肠转运、粪便的稠度和频率，因为它会改变肠道微生物群的组成。菊粉对便秘型肠易激综合征（IBS-C）患者的有益效果是明显的，但仍需要更多涉及大量患者样本的随机对照临床试验来提供更多证据。
